Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
7.6
86.01%
80%
—
6x
Every year
—
5 Years
Score7.6
Net Growth86.01%
Net Trend80%
Net Income Consistency—
Rev Growth6x
Rev TrendEvery year
Revenue Consistency—
Xeris Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 2M to $ 291M and net income went from -$ 125M to $ 554K. Revenue increased in every one of those 5 years; net income in 4.
Xeris Pharmaceuticals Inc currently holds a 5-year HDB Score of 7.6 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 8.49 | — |
1 Year2025-08-12 | $ 7.30 | 16.30% |
5 Years2021-08-12 | $ 2.43 | 249.38% |
All Time2018-06-21 | $ 20.22 | -58.01% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2018-06-21 |
|---|---|---|---|---|
| Price | $ 8.49 | $ 7.30 | $ 2.43 | $ 20.22 |
| Return | — | 16.30% | 249.38% | -58.01% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 335M | -$ 17M | $ 121M |
| 2025 | $ 291M | $ 554K | $ 111M |
| 2024 | $ 203M | -$ 54M | $ 71M |
| 2023 | $ 163M | -$ 62M | $ 72M |
| 2022 | $ 110M | -$ 94M | $ 121M |
| 2021 | $ 49M | -$ 122M | $ 102M |
| 2020 | $ 2M | -$ 125M | $ 75M |
| 2019 | $ 2M | -$ 125M | $ 75M |
| IPO2018 | $ 2M | -$ 60M | $ 112M |
Explore beyond XERS
You're looking at Xeris Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
